The Patent Finder

Antisense Therapeutics Ltd

Also on record
Records under this name other than the patents Antisense Therapeutics Ltd holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.

Back to Antisense Therapeutics Ltd

PatentTitleStatus Expires Confidence
US 8,759,314Methods for treating multiple sclerosis using antisense oligonucleotides
Lapsed on the fee record
Ended Jun 24, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jun 24, 2026From the USPTO record
US 9,885,048Method for reducing circulating leukocytes in a human subject
Lapsed on the fee record
Ended Feb 6, 2026 · From the USPTO record
Lapsed on the fee recordEnded Feb 6, 2026From the USPTO record
US 9,821,034Combination therapy
Lapsed on the fee record
Ended Nov 21, 2025 · From the USPTO record
Lapsed on the fee recordEnded Nov 21, 2025From the USPTO record
US 9,717,778Combination therapy
Lapsed on the fee record
Ended Aug 1, 2025 · From the USPTO record
Lapsed on the fee recordEnded Aug 1, 2025From the USPTO record
US 8,415,314Methods for Treating Multiple Sclerosis Using Antisense Oligonucleotides
Lapsed on the fee record
Ended Apr 9, 2025 · High confidence
Lapsed on the fee recordEnded Apr 9, 2025High confidence
US 8,299,039Modulation of Growth Hormone Receptor Expression and Insulin-Like Growth Factor Expression
Formerly held
Lapsed on the fee record
Ended Oct 30, 2024 · High confidence
Lapsed on the fee recordEnded Oct 30, 2024High confidence
US 8,623,836Modulation of Growth Hormone Receptor Expression and Insulin-Like Growth Factor Expression
Term ended
Term ended Apr 10, 2024 · High confidence
Term endedTerm ended Apr 10, 2024High confidence
US 9,371,530Modulation of growth hormone receptor expression and insulin-like growth factor expression
Term ended
Term ended Feb 27, 2024 · From the USPTO record
Term endedTerm ended Feb 27, 2024From the USPTO record
US 9,988,635Modulation of growth hormone receptor expression and insulin-like growth factor expression
Term ended
Ended no later than Feb 27, 2024 · From the USPTO record
Term endedEnded no later than Feb 27, 2024From the USPTO record
US 8,637,484Modulation of Growth Hormone Receptor Expression and Insulin-Like Growth Factor Expression
Term ended
Term ended Feb 26, 2024 · High confidence
Term endedTerm ended Feb 26, 2024High confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited